Partner with a central lab whose scientific capabilities keep pace with your drug development innovation
As precision medicine continues to redefine the science of drug development, our investment in technology and new testing platforms has kept pace with your needs.
Explore topics
Biomarkers are at the epicenter of today’s drug development and the pursuit of personalized medicines. They help define disease biology, drive patient identification and stratification, identify mechanism of action and understand the pharmacodynamic aspects of a drug.
Our scientists engage with you early in the process to better enable exploratory biomarker selection, trial design and the potential transition to companion diagnostic co-development.
Explore biomarkers
Adoptive cell therapies can deliver transformative approaches to patient care. Whether you are working with tumor-infiltrating lymphocytes, gene-modified T-cells expressing novel T-cell receptors, chimeric antigen receptor T-cells (CAR T) or CAR natural killer cells (CAR NK), we can support your programs across the entire development continuum. We utilize novel platforms and approaches critical to advanced therapy development, including next-generation sequencing, single-cell sequencing, digital spatial profiling and mass cytometry.
Reach your development goals on time and within budget leveraging our gene therapy expertise and resources, whether you’re developing a viral vector-based therapy or applying gene editing technologies.
Vaccine trials bring unique challenges that require more flexible solutions, including lab adaptability and scale. For large vaccine trials, like we saw for COVID-19 vaccines in the early 2020s, fast enrollment of 20,000-50,000 patients in 1-3 months generates tremendous pressure on kits, logistics, specimen storage and lab capacity. These multinational “follow the virus” trials frequently have numerous protocol amendments and short timelines for specimen processing. Labcorp’s central lab has a vaccines trial track record you can trust.
Precision medicine demands patient stratification—requiring identification of patients more likely to benefit from therapy. CDx also enables reduced development time and Rx development costs and can result in more favorable reimbursement and illustrate comparative effectiveness.
No matter what therapeutic area or disease indication your program is focused on, rely on our extensive, documented clinical trial experience across all therapeutic indications.
Explore key therapeutic areas
